PATENT CLAIM ANALYSIS

Application Number: 15957469
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-08
Patent Classification: ["514", "170000"]

Abstract:
The present disclosure relates to the use of GnRH receptor antagonists used in the treatment of endometriosis or uterine fibroids. In particular, the present disclosure describes a method of treating endometriosis or uterine fibroids, where the method involves the administration of elagolix, and where the method may further involve the co-administration of rifampin or ketoconazole.

Claim (Index 2):
The method according to  claim 1 , wherein the patient is treated a dose of less than 150 mg once per day by administering once per day an amount of elagolix less than 150 mg.

Metadata:
- Claim Count in Document: 71.0
- Percentile: 91.0
- Lexical Diversity: 1.62162
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15254419', '11715509', '15719636', '13128459', '10948608']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7169746062538999
- 35 USC 102 Novelty (BERT): 0.6705907463560378
- Combined Prediction Score: 0.7123362202641137
- Mean Citation Score: 298.140414
- Max Citation Score: 637.58734
- Similarity Product: 634.7144145908035

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test